CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY

Objective: To evaluate the efficacy of recombinant factor VIII FC fusion protein in haemophilia A patient receiving on demand treatment only. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Hematology, Armed Forces Institute of Pathology and Pakistan...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Saima Zahir, Tahira Zafar, Altaf Hussain, Hamid Saeed Malik, Pervez Ahmed, Saleem Ahmed Khan
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	hemophilia a recombinant factor viii recombinant factor viii fc fusion protein Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c23e28d5cefa4fad8017bd77710391d3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c23e28d5cefa4fad8017bd77710391d3
record_format	dspace
spelling	oai:doaj.org-article:c23e28d5cefa4fad8017bd77710391d32021-12-02T18:01:28ZCLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY0030-96482411-884210.51253/pafmj.v71i1.2674https://doaj.org/article/c23e28d5cefa4fad8017bd77710391d32021-02-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/2674https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To evaluate the efficacy of recombinant factor VIII FC fusion protein in haemophilia A patient receiving on demand treatment only. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Hematology, Armed Forces Institute of Pathology and Pakistan Hemophilia Welfare Society, Rawalpindi, from Jun to Dec 2017. Methodology: Eighty-nine male patients of Hemophilia A already receiving recombinant factor VIII (20-30 Units/kg) on demand, with no history of inhibitors were included in study. Patients were divided as per age into paediatric and adult group and also on the basis of their basal factor VIII levels into severe, moderate and mild groups. Same patients were switched to recombinant factor VIII FC fusion protein (20-30 Units/kg) and its efficacy was measured and compared with recombinant Factor VIII in terms of dose requirement, injections, bleeds in six month period, presence of inhibitors and side effects. Results: Eighty nine male patients were studied. There was significant reduction in dose from median value of 5750 units for group I to 4000 units for group II. Number of bleed in six month period were reduced from 5.3 in group I to 4.5 in group II. Number of injections were reduced on average to 1-2 injection per bleed in group II. No inhibitors were detected in group II. Conclusion: rFVIII Fc fusion protein has prolong activity and results in reduction of total dose, number of bleed, dose per bleed and has reduced antigenecity.Saima ZahirTahira ZafarAltaf HussainHamid Saeed MalikPervez AhmedSaleem Ahmed KhanArmy Medical College Rawalpindiarticlehemophilia arecombinant factor viiirecombinant factor viii fc fusion proteinMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss 1, Pp 62-66 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hemophilia a recombinant factor viii recombinant factor viii fc fusion protein Medicine R Medicine (General) R5-920
spellingShingle	hemophilia a recombinant factor viii recombinant factor viii fc fusion protein Medicine R Medicine (General) R5-920 Saima Zahir Tahira Zafar Altaf Hussain Hamid Saeed Malik Pervez Ahmed Saleem Ahmed Khan CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY
description	Objective: To evaluate the efficacy of recombinant factor VIII FC fusion protein in haemophilia A patient receiving on demand treatment only. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Hematology, Armed Forces Institute of Pathology and Pakistan Hemophilia Welfare Society, Rawalpindi, from Jun to Dec 2017. Methodology: Eighty-nine male patients of Hemophilia A already receiving recombinant factor VIII (20-30 Units/kg) on demand, with no history of inhibitors were included in study. Patients were divided as per age into paediatric and adult group and also on the basis of their basal factor VIII levels into severe, moderate and mild groups. Same patients were switched to recombinant factor VIII FC fusion protein (20-30 Units/kg) and its efficacy was measured and compared with recombinant Factor VIII in terms of dose requirement, injections, bleeds in six month period, presence of inhibitors and side effects. Results: Eighty nine male patients were studied. There was significant reduction in dose from median value of 5750 units for group I to 4000 units for group II. Number of bleed in six month period were reduced from 5.3 in group I to 4.5 in group II. Number of injections were reduced on average to 1-2 injection per bleed in group II. No inhibitors were detected in group II. Conclusion: rFVIII Fc fusion protein has prolong activity and results in reduction of total dose, number of bleed, dose per bleed and has reduced antigenecity.
format	article
author	Saima Zahir Tahira Zafar Altaf Hussain Hamid Saeed Malik Pervez Ahmed Saleem Ahmed Khan
author_facet	Saima Zahir Tahira Zafar Altaf Hussain Hamid Saeed Malik Pervez Ahmed Saleem Ahmed Khan
author_sort	Saima Zahir
title	CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY
title_short	CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY
title_full	CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY
title_fullStr	CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY
title_full_unstemmed	CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY
title_sort	clinical efficacy of recombinant factor viii fc fusion protein in haemophilia a patient receiving on demand treatment only
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doaj.org/article/c23e28d5cefa4fad8017bd77710391d3
work_keys_str_mv	AT saimazahir clinicalefficacyofrecombinantfactorviiifcfusionproteininhaemophiliaapatientreceivingondemandtreatmentonly AT tahirazafar clinicalefficacyofrecombinantfactorviiifcfusionproteininhaemophiliaapatientreceivingondemandtreatmentonly AT altafhussain clinicalefficacyofrecombinantfactorviiifcfusionproteininhaemophiliaapatientreceivingondemandtreatmentonly AT hamidsaeedmalik clinicalefficacyofrecombinantfactorviiifcfusionproteininhaemophiliaapatientreceivingondemandtreatmentonly AT pervezahmed clinicalefficacyofrecombinantfactorviiifcfusionproteininhaemophiliaapatientreceivingondemandtreatmentonly AT saleemahmedkhan clinicalefficacyofrecombinantfactorviiifcfusionproteininhaemophiliaapatientreceivingondemandtreatmentonly
_version_	1718379011862691840

CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY

Ejemplares similares